[Effects of proteasome inhibitors on leukemias].

Abstract

The proteasome is primarily responsible for intracellular protein degradation. The abnormality of its activity is sign of tumorigenesis. It was confirmed that proteasome inhibitors have activities against a variety of malignancies. Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale. Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.

• Authors: Shu-Qing Lü, Jian-Min Yang, Jian-Min Wang
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 15 Issue 4 Pg. 896-900 (Aug 2007) ISSN: 1009-2137 [Print] China
• PMID: 17708829 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Boronic Acids
• Protease Inhibitors
• Proteasome Inhibitors
• Pyrazines
• Bortezomib

Topics

• Animals
• Boronic Acids (therapeutic use)
• Bortezomib
• Humans
• Leukemia (drug therapy, enzymology)
• Multiple Myeloma (drug therapy)
• Protease Inhibitors (therapeutic use)
• Proteasome Inhibitors
• Pyrazines (therapeutic use)